Guerbet Stock Rises by 5.72%: +18% in One Week After Months of Decline
On Tuesday midday, Guerbet's stock price increased by 5.72%, trading at 10.54 euros after closing at 9.97 euros the previous day. This surge comes within a context of a notable weekly rebound, with an 18% increase over seven days, although the medical imaging contrast agent specialist has seen a significant decline over three months (-26.5%) and over one year (-47.95%).
Guerbet's progress this Tuesday is part of a recovery movement following several weeks of sharp decline. The stock is now trading above its 20-day moving average, which is at 10.29 euros, a breakthrough indicating a short-term momentum gain. However, the price remains far from its 50-day and 200-day averages, at 12.33 and 16.33 euros respectively, highlighting the significant undervaluation accumulated in recent months.
The Relative Strength Index (RSI), which measures the speed of upward and downward movements, is at 41: a moderate level indicating that the stock is not in an overbought zone despite the recent rebound. The technical support threshold identified at 8.20 euros was not tested during the last downward phase, while the most relevant resistance lies at 13.72 euros, which is more than 30% above the current price.
Crucial Weeks Ahead for Guerbet Fundamentally
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The upcoming weeks are crucial for Guerbet fundamentally. The publication of the first quarter 2026 revenue is expected on April 23, followed by the annual general meeting of shareholders scheduled for May 22. These events will assess the commercial trajectory of the group, as the stock has lost nearly half of its value over the past year.
The movement of the day occurs in a mixed market environment. The CAC 40 is up by 0.73% during the session, at 7,828.88 points, while the SBF 120 gains 0.77%. However, overall volatility remains high, with the VIX at 31.05 points at the close of March 27, indicating significant market stress. Guerbet's beta, at 0.72, shows less sensitivity to general market fluctuations, which partly mitigates the direct influence of the macroeconomic context on the stock.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux / imagerie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 379,2 millions d'euros
Quarterly revenue: 379,2 millions d'euros
Revenue growth: -2,2 %
Guidance from the release
Objectifs financiers intégrant l'impact significatif de la situation du site de Raleigh, Free Cash-Flow fortement négatif
Risks mentioned
Non-respect anticipé du ratio d'endettement net/EBITDA de 3,5x testé au 30 juin 2026
Refinancement à négocier avec les partenaires financiers d'ici au 31 octobre 2026
Free Cash-Flow 2026 attendu fortement négatif entre -50 M€ et -70 M€
Opportunities identified
Normalisation complète attendue du site de Raleigh d'ici fin 2026
Forte croissance en France (+9,0 %) après absorption de la réforme de l'approvisionnement
Radiologie Interventionnelle en hausse de 4,7 % portée par le Lipiodol
Outlook / guidance
Expected EBITDA: 62,9 millions d'euros
Management commentary: Chiffre d'affaires entre stable et en légère décroissance à TCC et périmètre comparable ; Taux de marge d'EBITDA retraité 3 de l'ordre de 8%, incluant environ 35 M€ liés aux coûts du plan de remise en conformité sur le site de Raleigh ; Free Cash-Flow compris entre -50 M€ et -70 M€
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.